

# Can taking amitriptyline tablets stop long-term pain from shingles?

<b>Submission date</b> 17/01/2022	<b>Recruitment status</b> No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 27/01/2022	<b>Overall study status</b> Ongoing	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
<b>Last Edited</b> 15/07/2025	<b>Condition category</b> Infections and Infestations	<input type="checkbox"/> Individual participant data <input checked="" type="checkbox"/> Record updated in last year

## Plain English summary of protocol

### Background and study aims

Shingles is a viral infection that causes a painful rash. This study aims to find out whether taking a low dose of amitriptyline soon after getting shingles can prevent the long-term pain associated with shingles

### Who can participate?

Patients aged over 50 years who have been diagnosed by their GP with shingles.

### What does the study involve?

Participants take tablets nightly for 10 weeks: half will be given low-dose amitriptyline and the other half will get placebo (dummy) tablets. Pain is assessed at 90 days after rash onset.

### What are the possible benefits and risks of participating?

If starting amitriptyline early on does help, it is a cheap medicine that would prevent prolonged, difficult-to-treat pain for thousands of people. However, amitriptyline commonly causes side effects such as dizziness, dry mouth and constipation. It can also cause problems when used together with some other tablets. This study is needed so doctors can be sure that any benefits outweigh any harm.

### Where is the study run from?

1. University of Bristol (UK)
2. Southampton University (UK)
3. Oxford University (UK)

### When is the study starting and how long is it expected to run for?

July 2021 to July 2025

### Who is funding the study?

National Institute for Health Research (NIHR) (UK)

### Who is the main contact?

athena-study@bristol.ac.uk

**Study website**

<https://athena-study.bristol.ac.uk/>

## Contact information

**Type(s)**

Scientific

**Contact name**

Dr Sian Wells

**Contact details**

Centre for Academic Primary Care  
Bristol Medical School  
University of Bristol  
Canyng Hall  
39 Whatley Rd  
Bristol  
United Kingdom  
BS8 2PS  
+44 (0)117 9287308  
[athena-study@bristol.ac.uk](mailto:athena-study@bristol.ac.uk)

**Type(s)**

Scientific

**Contact name**

Prof Matthew Ridd

**Contact details**

Centre for Academic Primary Care  
Bristol Medical School  
University of Bristol  
Canyng Hall  
39 Whatley Rd  
Bristol  
United Kingdom  
BS8 2PS  
+44 (0)117 33 14557  
[m.ridd@bristol.ac.uk](mailto:m.ridd@bristol.ac.uk)

## Additional identifiers

**EudraCT/CTIS number**

2021-001101-78

**IRAS number**

1003967

**ClinicalTrials.gov number**

Nil known

## **Secondary identifying numbers**

CPMS 50893, IRAS 1003967

# **Study information**

## **Scientific Title**

Amitriptyline for the prevention of post-herpetic neuralgia

## **Acronym**

ATHENA

## **Study objectives**

Prophylactic low-dose amitriptyline will reduce post-herpetic neuralgia in patients diagnosed with herpes zoster (shingles).

## **Ethics approval required**

Old ethics approval format

## **Ethics approval(s)**

Approved 18/10/2021, South West- Central Bristol Research Ethics Committee (Ground Floor, Temple Quay House, 2 The Square, Bristol, BS1 6PN, UK; +44 (0)207 104 8029, +44 (0)207 104 8068, +44 (0)207 104 8375; centralbristol.rec@hra.nhs.uk), REC ref: 21/SW/0130

## **Study design**

Randomized; Interventional; Design type: Treatment, Drug

## **Primary study design**

Interventional

## **Secondary study design**

Randomised controlled trial

## **Study setting(s)**

GP practice

## **Study type(s)**

Treatment

## **Participant information sheet**

<https://athena-study.blogs.bristol.ac.uk/files/2022/01/ATHENA-PIL.pdf>

## **Health condition(s) or problem(s) studied**

Shingles

## **Interventions**

Amitriptyline 10 mg tablets (or matched placebo tablet), increasing in 10 mg steps over 2 weeks as tolerated, to 30 mg maximum per day, for 70 days.

Total follow-up is 12 months, with participant surveys at baseline and 30, 60, 90, 120, 180 and 360 days after rash onset.

#### Randomisation:

Trial participants will be allocated in a 1:1 ratio to receive amitriptyline or placebo. Randomisation will be stratified by centre and minimised on age deciles, gender at birth, pain in the last 24 hours and shingles vaccination history. The randomisation sequence will be generated by the company Sealed Envelope™ using their online randomisation system, which will allocate the participant to a treatment arm. The person undertaking the randomisation and the participant will remain masked as to which treatment group this code refers.

#### Intervention Type

Drug

#### Phase

Not Applicable

#### Drug/device/biological/vaccine name(s)

Amitriptyline

#### Primary outcome measure

Presence/absence of postherpetic neuralgia measured using a cut-off of  $\geq 3/10$  on numerical rating scale average pain in last 24 hours; Timepoint(s): 90 days after rash onset

#### Secondary outcome measures

1. The safety, tolerability and acceptability of amitriptyline assessed using patient-completed medication use, problems and hospitalisation sections of questionnaire at 30, 60 and 90 days, and by direct report by participant or clinician
2. Masking of participants assessed using the bang binding index in patient questionnaires at 30, 60 and 90 days post rash onset
3. Shorter and longer-term outcomes of pain, quality of life, mental well-being and frailty, assessed using the Zoster Brief Pain Inventory (ZBPI), 9-item patient health questionnaire (PHQ-9), 7-item general anxiety disorder questionnaire (GAD-7) and Tilburg Frailty Indicator, at 0, 90, 180 and 360 days post rash onset
4. The cost-effectiveness of low dose amitriptyline to placebo for the prevention of PHN using EQ-5D-5L and patient-completed healthcare resource use questions at 0, 90, 180 and 360 days post rash onset, and GP electronic medical records for the 12-month study period
5. Use of healthcare resources and analgesics assessed using patient-completed medication and healthcare resource use questions at 90, 180 and 360 days post rash onset, and GP electronic medical records for the 12-month study period

#### Overall study start date

01/07/2021

#### Completion date

31/07/2025

## Eligibility

#### Key inclusion criteria

1. Adults aged  $\geq 50$  years
2. Clinical diagnosis of herpes zoster (HZ)
3. Rash onset  $< 144$  hours

**Participant type(s)**

Patient

**Age group**

Adult

**Lower age limit**

50 Years

**Sex**

Both

**Target number of participants**

Planned Sample Size: 846; UK Sample Size: 846

**Total final enrolment**

878

**Key exclusion criteria**

1. Inability to give informed consent
2. Third or more episode of herpes zoster
3. Known adverse reaction to amitriptyline or contraindications (monoamine oxidase inhibitors)
4. Current/recent (within previous two weeks) use of a tricyclic antidepressant
5. Prolonged QT interval or concomitant drugs that prolong the QT interval
6. Suicidal ideation
7. Heart block
8. Recent myocardial infarction ( $< 4$  weeks)
9. Immunosuppression
10. Significant bradycardia
11. Uncompensated heart failure
12. Hyperthyroidism
13. Severe liver disease
14. Pheochromocytoma
15. Urinary retention
16. If female; current or planned (in next 3 months) pregnancy or breastfeeding
17. Currently (or recently, within the previous 4 months) enrolled in another CTIMP

**Date of first enrolment**

30/03/2022

**Date of final enrolment**

30/04/2025

**Locations****Countries of recruitment**

England

United Kingdom

**Study participating centre**

**University of Bristol**

Senate House  
Tyndall Avenue  
Bristol  
United Kingdom  
BS8 1TH

**Study participating centre**

**University of Oxford**

University Offices  
Oxford  
United Kingdom  
OX1 2JD

**Study participating centre**

**University of Southampton**

University Road  
Southampton  
United Kingdom  
SO17 1BJ

## **Sponsor information**

**Organisation**

University of Bristol

**Sponsor details**

1 Cathedral Square  
Trinity Street  
College Green  
Bristol  
England  
United Kingdom  
BS1 5DD  
+44 (0)117 394 0177  
[research-governance@bristol.ac.uk](mailto:research-governance@bristol.ac.uk)

**Sponsor type**

University/education

**Website**

<http://bristol.ac.uk/>

**ROR**

<https://ror.org/0524sp257>

## Funder(s)

**Funder type**

Government

**Funder Name**

NIHR Evaluation, Trials and Studies Co-ordinating Centre (NETSCC); Grant Codes: NIHR129720

## Results and Publications

**Publication and dissemination plan**

Planned publication in a high-impact peer-reviewed journal in approximately 2025. The researchers will publish a protocol in due course.

**Intention to publish date**

30/04/2027

**Individual participant data (IPD) sharing plan**

The final anonymised trial data set will be stored as restricted data on the data.bris research data repository for at least 5 years after the end of the study. Data will be made available after the end of the study to approved bona fide researchers only after their host institution has signed a data access agreement. Details of how to request access are available at the University of Bristol's data repository website.

**IPD sharing plan summary**

Stored in non-publicly available repository

**Study outputs**

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">HRA research summary</a>			28/06/2023	No	No
<a href="#">Other publications</a>	Qualitative interviews	31/07/2024	01/08/2024	Yes	No